MAPK3 and hepatocellular carcinoma: GCDCA treatment of HepG2 cell lines activates ERK1 and ERK2, induces phosphorylation of Mcl-1 at the T163 site and is a potential carcinogen in the development of HCC (Liao et al., 2011).